UK's Hemogenyx Pharmaceuticals H1 loss widens on share-based payments
UK's Hemogenyx Pharmaceuticals H1 loss widens on share-based payments
Overview
UK biopharma firm's H1 loss widened, driven by non-cash share-based payment charge
Company raised £5.6 mln in H1 to fund clinical development of lead CAR-T therapy
Operating costs fell yr/yr excluding share-based payments, reflecting manufacturing outsourcing savings
Outlook
Company prioritises dose escalation in adult trial and enrolment of first paediatric patients
Hemogenyx aims to complete technology transfer to Cellin and begin treating patients in Estonia
Result Drivers
SHARE-BASED PAYMENT CHARGE - Widened H1 loss was mainly attributed to a non-cash share-based payment expense from options granted
MANUFACTURING OUTSOURCING - Underlying operating costs fell after outsourcing HG-CT-1 manufacturing to Made Scientific
Company press release: ID:nRSb4463Wa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
H1 Loss Per Share |
| GBP 1.02 |
|
Reuters Recommended Reads
Sept 25 - US FDA approves Mirum's drug for rare bone disorder
Sept 25 - ADARx Pharmaceuticals shares soar in Nasdaq debut after upsized IPO
Sept 25 - Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)